Literature DB >> 31304741

A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes.

Matthew K Matlock1, Abhik Tambe1, Jack Elliott-Higgins1, Ronald N Hines2, Grover P Miller3, S Joshua Swamidass4.   

Abstract

Pediatric patients are at elevated risk of adverse drug reactions, and there is insufficient information on drug safety in children. Complicating risk assessment in children, there are numerous age-dependent changes in the absorption, distribution, metabolism, and elimination of drugs. A key contributor to age-dependent drug toxicity risk is the ontogeny of drug metabolism enzymes, the changes in both abundance and type throughout development from the fetal period through adulthood. Critically, these changes affect not only the overall clearance of drugs but also exposure to individual metabolites. In this study, we introduce time-embedding neural networks in order to model population-level variation in metabolism enzyme expression as a function of age. We use a time-embedding network to model the ontogeny of 23 drug metabolism enzymes. The time-embedding network recapitulates known demographic factors impacting 3A5 expression. The time-embedding network also effectively models the nonlinear dynamics of 2D6 expression, enabling a better fit to clinical data than prior work. In contrast, a standard neural network fails to model these features of 3A5 and 2D6 expression. Finally, we combine the time-embedding model of ontogeny with additional information to estimate age-dependent changes in reactive metabolite exposure. This simple approach identifies age-dependent changes in exposure to valproic acid and dextromethorphan metabolites and suggests potential mechanisms of valproic acid toxicity. This approach may help researchers evaluate the risk of drug toxicity in pediatric populations.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31304741      PMCID: PMC6933754          DOI: 10.1021/acs.chemrestox.9b00223

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  67 in total

Review 1.  Idiosyncratic drug reactions: the reactive metabolite syndromes.

Authors:  S R Knowles; J Uetrecht; N H Shear
Journal:  Lancet       Date:  2000-11-04       Impact factor: 79.321

Review 2.  Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1.

Authors:  Frank J Gonzalez
Journal:  Mutat Res       Date:  2005-01-06       Impact factor: 2.433

Review 3.  Cytochrome P450s and other enzymes in drug metabolism and toxicity.

Authors:  F Peter Guengerich
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

4.  Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity.

Authors:  K Allegaert; B J Anderson; R Verbesselt; A Debeer; J de Hoon; H Devlieger; J N Van Den Anker; D Tibboel
Journal:  Br J Anaesth       Date:  2005-06-10       Impact factor: 9.166

5.  Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity.

Authors:  S L Iverson; J P Uetrecht
Journal:  Chem Res Toxicol       Date:  2001-02       Impact factor: 3.739

6.  Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

Authors:  Trevor N Johnson; Amin Rostami-Hodjegan; Geoffrey T Tucker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.

Authors:  D Lacroix; M Sonnier; A Moncion; G Cheron; T Cresteil
Journal:  Eur J Biochem       Date:  1997-07-15

Review 8.  Managing the challenge of chemically reactive metabolites in drug development.

Authors:  B Kevin Park; Alan Boobis; Stephen Clarke; Chris E P Goldring; David Jones; J Gerry Kenna; Craig Lambert; Hugh G Laverty; Dean J Naisbitt; Sidney Nelson; Deborah A Nicoll-Griffith; R Scott Obach; Philip Routledge; Dennis A Smith; Donald J Tweedie; Nico Vermeulen; Dominic P Williams; Ian D Wilson; Thomas A Baillie
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

Review 9.  Assessing the economic impact of adverse drug effects.

Authors:  Rosa Rodríguez-Monguió; María José Otero; Joan Rovira
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

10.  Modeling Reactivity to Biological Macromolecules with a Deep Multitask Network.

Authors:  Tyler B Hughes; Na Le Dang; Grover P Miller; S Joshua Swamidass
Journal:  ACS Cent Sci       Date:  2016-07-29       Impact factor: 14.553

View more
  2 in total

1.  Use of Biomarker Data and Relative Potencies of Mutagenic Metabolites to Support Derivation of Cancer Unit Risk Values for 1,3-Butadiene from Rodent Tumor Data.

Authors:  Christopher R Kirman; Sean M Hays
Journal:  Toxics       Date:  2022-07-15

Review 2.  No population left behind: Improving paediatric drug safety using informatics and systems biology.

Authors:  Nicholas P Giangreco; Jonathan E Elias; Nicholas P Tatonetti
Journal:  Br J Clin Pharmacol       Date:  2021-01-19       Impact factor: 3.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.